Clinical innovations mark the latest version of
SuperSonic Imagine’s premium ultrasound system
SuperSonic Imagine (Euronext: SSI, FR0010526814), a company
specialising in ultrasound medical imaging, is excited to introduce
the newest version of its premium ultrasound system, Aixplorer®
Ultimate, the result of French research and innovation using
SuperSonic Imagine’s exclusive UltraFast™ technology. UltraFast,
which offers acquisition rates 200 times faster than conventional
ultrasound systems, has opened up the possibility of new imaging
modalities that are now used daily by physicians.
“Since 2009, SuperSonic Imagine has been at the forefront of
medical imaging with the Aixplorer ultrasound system and its
revolutionary, software-only architecture. Our company has always
been at the cutting edge of innovation, continuously developing
improved imaging modalities and offering better care and treatment
for patients,” said SuperSonic Imagine CEO Michèle Lesieur.
The Aixplorer Ultimate incorporates new architecture boasting
4.5 times more computing power than previous Aixplorer models. It
also has a new streamlined look and intuitive user interface. Ease
of use has been improved dramatically, especially for extended
periods of work. Ultimate also incorporates the very latest
UltraFast innovation – Needle PL.U.S – enabling simultaneous
visualisation of anatomical structures, biopsy needles and their
trajectory with a high level of precision. This new feature sits
alongside other modalities introduced over the past 8 years by SSI:
ShearWave™ Elastography (SWE™), used to view and measure the
stiffness of tissue in real time using color mapping; UltraFast
Doppler, which combines Pulsed Doppler and Color Doppler in a
single sweep; Angio PL.U.S, offering unrivalled resolution for
imaging microvascularisation in lesions; and TriVu (B mode + SWE +
Color+), a new triplex modality combining three types of diagnostic
information into a single examination. These innovations provide
fast and reliable access to diagnostic information, an essential
resource for the diagnosis and assessment of major diseases such as
chronic liver disease and breast and prostate cancers.
Jacques Souquet, Co-Founder and Chief Innovation Officer at
SuperSonic Imagine, said, “Aixplorer Ultimate is the result of 8
years of research and development. This is a much more reliable,
faster and innovative ultrasound system, designed to meet new
imaging needs when screening, diagnosing and monitoring major
diseases. Discussed in more than 400 publications, the SWE
technology employed in this system has demonstrated its clinical
advantages associated with the detection and characterisation of
many different diseases across a broad spectrum of
applications.”
In the breast, Aixplorer Ultimate helps to improve the
identification of malignant or benign lesions and to reduce the
number of negative biopsies.
The advantages of SWE in the diagnosis of mammary lesions have
been demonstrated in more than 100 publications, including an
international study involving more than 1,600 patients1-2. When
this technology is combined with conventional ultrasound, diagnoses
can be more accurate, significantly reducing the number of false
positives, and thus the number of unnecessary biopsies.
In the liver, Aixplorer Ultimate can assess levels of
fibrosis and NASH without a biopsy.
SWE makes it possible to quantify liver stiffness in a
non-invasive manner. Liver stiffness is a key parameter when
diagnosing, assessing and monitoring liver fibrosis. That is why
more than 100 international articles agree in demonstrating the
reliability and effectiveness of this technology in this particular
field.
In the prostate, Aixplorer Ultimate provides effective
guidance for biopsies.
Clinical studies show that SWE considerably increases biopsy
efficiency. Its colour mapping helps doctors target sampling and
keep the number of samples to a minimum.
SWE is also frequently used in musculoskeletal imaging to view
muscles, tendons, ligaments and joints, for the purposes of
tendinopathy diagnosis and monitoring. Aixplorer, with its
UltraFast technology, is also every effective in vascular and
pediatric examinations.
With Aixplorer Ultimate, the most advanced version of its
ultrasound platform, SuperSonic Imagine has found a way to address
the clinical challenges of a wide range of clinical needs among
radiologists and patients.
1 ShearWave Elastography for breast masses is highly
reproducible. Cosgrove DO et al. European Radiology 2011 Dec 312
Shear-wave Elastography Improves the Specificity of Breast US: The
BE1 Multinational Study of 939 Masses Radiology (2012
Feb;262(2):435-449) by Wendie A. Berg, MD, PhD, et al. Radiology.
2012 Feb;262(2):435-49. doi: 10.1148/radiol.11110640. Eur Radiol.
2012 May; 22(5): 1023–1032.
About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France),
SuperSonic Imagine is a company specializing in medical imaging.
The company designs, develops and markets a revolutionary
ultrasound system, Aixplorer®, with an UltraFast™ platform that can
acquire images 200 times faster than conventional ultrasound
systems. In addition to providing exceptional image quality, this
unique technology is the foundation of several innovations which
have changed the paradigm of ultrasound imaging: ShearWave™
Elastography (SWETM), UltraFast™ Doppler, Angio PL.U.S – Planewave
UltraSensitiveTM Imaging and more recently TriVu. ShearWave
Elastography allows physicians to visualize and analyze the
stiffness of tissue in a real-time, reliable, reproducible and
non-invasive manner. This criteria has become an important
parameter in diagnosing potentially malignant tissue or other
diseased tissue. As of today, over 300 peer-reviewed publications
have demonstrated the value of SWE for the clinical management of
patients with a wide range of diseases. UltraFast Doppler combines
Color Flow Imaging and Pulsed Wave Doppler into one simple exam,
providing physicians with exam results simultaneously and helping
to increase patient throughput. The latest innovation, Angio
PL.U.S, provides a new level of microvascular imaging through
significantly improved color sensitivity and spatial resolution
while maintaining exceptional 2D imaging.
SuperSonic Imagine has been granted regulatory clearances for
the commercialization of Aixplorer in key global markets.
SuperSonic Imagine is a listed company since April 2014 on the
Euronext, symbol SSI.
For more information about SuperSonic Imagine, please go to
www.supersonicimagine.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170731005845/en/
SuperSonic ImagineMarketing & CommunicationEmmanuelle
Vella, +33 4 86 79 03
27emmanuelle.vella@supersonicimagine.comorNewCapInvestor
Relations – EUPierre Laurent / Florent Alba,
+33144719855supersonicimagine@newcap.frorPascale
CommunicationMedia Relations - USAmy Phillips, +1
412-327-9499amy@pascalecommunications.com
Stage Stores (NYSE:SSI)
Historical Stock Chart
From Apr 2024 to May 2024
Stage Stores (NYSE:SSI)
Historical Stock Chart
From May 2023 to May 2024